Management of Hyperuricemia in Patients with Impaired Renal Function

Initial Assessment and Treatment Approach

For a patient with hyperuricemia and moderate renal impairment, the American College of Rheumatology recommends initiating allopurinol at a low dose and gradually titrating upward to achieve a serum uric acid target below 6 mg/dL, with careful monitoring for adverse effects, in patients with eGFR of 45 ml/min and uric acid levels of 9.8 mg/dL 1, 2
The primary goal of treatment is to reduce serum urate levels below 6 mg/dL to prevent gout attacks, tophi formation, and potential further kidney damage in patients with hyperuricemia and renal impairment 3, 4
Allopurinol remains the first-line urate-lowering therapy even in patients with renal impairment, according to the European League Against Rheumatism 5, 3

The American College of Rheumatology recommends starting allopurinol at a low dose of 100 mg/day (or 50 mg/day with eGFR <30 ml/min) in patients with renal impairment 1, 2
Gradually titrate the dose upward every 2-5 weeks to reach the target serum uric acid level <6 mg/dL in patients with hyperuricemia and renal impairment 2, 6
Despite traditional concerns, allopurinol dose can be raised above 300 mg daily even with renal impairment, provided there is adequate patient education and monitoring for toxicity (rash, pruritus, elevated liver enzymes) in patients with eGFR of 45 ml/min and uric acid levels of 9.8 mg/dL 1, 7

Consider HLA-B*5801 testing before initiating allopurinol in high-risk populations (Korean patients with stage 3 or worse CKD; Han Chinese and Thai patients regardless of renal function) to reduce the risk of allopurinol hypersensitivity syndrome 1, 2
Uricosuric agents like probenecid are not recommended as first-line therapy in patients with creatinine clearance <50 ml/min due to the increased risk of renal stone formation 1, 2

If allopurinol is not tolerated or ineffective despite appropriate dosing, consider febuxostat as an alternative in patients with hyperuricemia and renal impairment, according to the European League Against Rheumatism 7, 3
Febuxostat can be used without dose adjustment in patients with mild to moderate renal impairment, with a strength of evidence rated as high 3
In refractory cases, consider combination therapy by adding agents with uricosuric effects (fenofibrate or losartan) to xanthine oxidase inhibitors in patients with hyperuricemia and renal impairment 2, 7

Avoid starting with standard doses (300 mg) in patients with renal impairment, as this increases risk of toxicity, with a strength of evidence rated as moderate 6
Avoid uricosuric agents as monotherapy in patients with history of urolithiasis or elevated urinary uric acid, with a strength of evidence rated as low 2

For a patient on 700mg daily allopurinol with increased creatinine and decreased GFR, the dose should be gradually reduced to a level appropriate for their renal function, starting with an immediate reduction to 300mg daily, followed by further titration based on serum uric acid levels and renal function monitoring 8
Assess current serum uric acid level, with a target of maintaining levels <6 mg/dL to prevent gout flares, as recommended by the American College of Rheumatology 8, 9

After initial reduction to 300mg daily, implement a step-down approach with monitoring every 2-4 weeks of both serum uric acid and renal function, according to the European League Against Rheumatism 8
If serum uric acid target cannot be achieved with the adjusted allopurinol dose, consider switching to febuxostat, which can be used without dose adjustment in mild to moderate renal impairment, as suggested by the American College of Rheumatology 8

Monitor serum uric acid levels every 2-4 weeks during dose adjustment to ensure levels remain below 6 mg/dL, as recommended by the European League Against Rheumatism 8, 9
Be alert for potential gout flares during dose adjustment, which may require prophylactic treatment, according to the American College of Rheumatology 8, 10

For patients with severe tophaceous gout and inadequate response to adjusted allopurinol, consider adding a uricosuric agent (except in patients with eGFR <30 mL/min), as recommended by the American College of Rheumatology 8, 11
Consider combination therapy by adding agents with uricosuric effects (fenofibrate or losartan) to the reduced dose of allopurinol, according to the American College of Rheumatology 11

Once stabilized on an appropriate dose, continue regular monitoring of serum uric acid and renal function every 3-6 months, as recommended by the European League Against Rheumatism 8
Maintain serum uric acid levels <6 mg/dL long-term to prevent gout attacks and crystal deposition, according to the American College of Rheumatology 8, 9

Allopurinol remains the first-line agent even with moderate renal impairment, with an estimated CrCl approximately 40-50 mL/min, according to the American College of Rheumatology 12
The European League Against Rheumatism recommends that uricosuric agents, such as probenecid, are contraindicated with creatinine clearance <50 mL/min, making them unsuitable for patients with renal impairment 12, 13

The American College of Rheumatology suggests that colchicine can be used for flare prophylaxis, but the dose should be reduced in patients with renal impairment to prevent toxicity 12, 13